Core Insights - The integration of artificial intelligence (AI) into business operations is accelerating, evolving from an auxiliary tool to a new type of "productivity system" in the context of a restructured global trade landscape and a stable Chinese economy [2] - The "2025 New Beijing News Beike Finance Annual Conference" highlighted the theme "China's Economy: Open and Resilient Co-Growth," where the "China Entrepreneur AI Application Research Report (2025)" was released, revealing ten trends in AI application among Chinese enterprises [2] Group 1: AI Deployment Status - Nearly 90% of enterprises have implemented AI in some capacity, indicating a shift from optional use to a systematic variable that enhances efficiency and drives organizational change [6][29] - 65.63% of enterprises have established or are planning to set up AI-related organizational structures, focusing on decision-making, research and development, and customer service [8][29] - The preferred methods for AI deployment include public APIs (41.41%), customized models (34.38%), and embedded tools (30.47%), with a focus on content generation, customer insights, and internal automation [10] Group 2: AI Transformation and Governance - 65.63% of enterprises have established or plan to create AI-related positions, with the majority integrating these roles into data/IT departments, marking a transition from project-based to organizational AI development [12] - 11.72% of enterprises have established AI governance systems, while 51.57% have partial regulations or governance plans, indicating a nascent stage of governance development [17] - 78.13% of enterprises anticipate that AI will optimize or significantly transform industry structures within three years, highlighting the perceived strategic importance of AI [20][24] Group 3: Expectations and Support Needs - 68.75% of enterprises expect AI to yield significant benefits in cost reduction and efficiency improvement, with positive expectations also noted in user experience and competitive differentiation [22] - There is a strong demand for supportive policies, with 62.5% of enterprises calling for AI talent training, 60.16% seeking subsidies for small and medium-sized enterprises, and 51.56% focusing on data compliance [26] - The report emphasizes that AI has become a critical lever for enhancing efficiency, resilience, and competitiveness, while also noting challenges related to organizational capability, governance, and transformation pathways [29]

Core Viewpoint - The company has responded to the regulatory inquiry regarding its 2024 annual report, addressing various aspects of its business performance and financial metrics, particularly focusing on revenue changes across different segments and the impact of market conditions on its operations [1][2]. Business Performance - In 2024, the company reported total revenue of 381.24 million yuan, with standardized model revenue at 164.77 million yuan, showing a year-on-year increase of 16.58%. However, model breeding revenue decreased by 8.60% to 90.06 million yuan, while drug efficacy evaluation and phenotypic analysis revenue increased by 7.14% to 53.20 million yuan [2][4]. - Domestic and international revenue were 325.43 million yuan and 53.06 million yuan respectively, with gross margins of 41.66% and 70.9%, indicating a 31.88% year-on-year growth in international revenue [2][4]. Revenue Analysis - The company conducted a volume and price analysis of revenue changes across different business segments, noting that the increase in standardized model revenue was due to a rise in project quantity, while the decline in customized model revenue was attributed to a decrease in project quantity [3][5]. - The company observed a general decline in project prices across all business types due to intensified market competition and increased customer price sensitivity [4][5]. Customer Segmentation - The customer base primarily consists of research and industrial clients, with research clients having a higher number but lower average transaction values compared to industrial clients [6][8]. - The revenue contribution from research clients and industrial clients remained stable year-on-year, with customized model business mainly serving research clients [6][8]. Gross Margin Comparison - The gross margin for standardized models increased by 7.26 percentage points, attributed to stable demand from research clients and improved cost control measures [7][9]. - The gross margin for breeding services decreased by 13.97 percentage points due to increased market competition and underutilization of breeding facilities, leading to higher unit costs [7][9]. International Business Growth - The company expanded its international market presence, resulting in significant revenue growth from overseas operations, with higher average sales prices compared to domestic sales [10][12]. - The gross margin for international sales was significantly higher than domestic sales, reflecting industry norms [10][12]. Inventory Management - As of the end of 2024, the company's inventory balance was 12.67 million yuan, a decrease of 19.95% year-on-year, with inventory turnover rates significantly higher than industry peers [19][21]. - The reduction in inventory was attributed to improved cost control, production efficiency, and the completion of long-term projects, particularly in drug efficacy evaluation and phenotypic analysis [19][21].